Sareum (SAR) Competitors GBX 14.50 -2.00 (-12.12%) As of 10:35 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock SAR vs. PHD, FEN, NMT, IGR, GLV, TSI, CGO, MYN, IDE, and EVGShould you be buying Sareum stock or one of its competitors? The main competitors of Sareum include Proactis (PHD), Frenkel Topping Group (FEN), Neometals (NMT), IG Design Group (IGR), Glenveagh Properties (GLV), Two Shields Investments Plc (TSI.L) (TSI), Contango (CGO), Mayan Energy (MYN), IDE Group (IDE), and Evgen Pharma (EVG). These companies are all part of the "financial services" industry. Sareum vs. Its Competitors Proactis Frenkel Topping Group Neometals IG Design Group Glenveagh Properties Two Shields Investments Plc (TSI.L) Contango Mayan Energy IDE Group Evgen Pharma Sareum (LON:SAR) and Proactis (LON:PHD) are both small-cap financial services companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings. Is SAR or PHD more profitable? Proactis' return on equity of 0.00% beat Sareum's return on equity.Company Net Margins Return on Equity Return on Assets SareumN/A -270.25% -113.80% Proactis N/A N/A N/A Does the media refer more to SAR or PHD? In the previous week, Sareum had 1 more articles in the media than Proactis. MarketBeat recorded 1 mentions for Sareum and 0 mentions for Proactis. Sareum's average media sentiment score of 1.38 beat Proactis' score of 0.00 indicating that Sareum is being referred to more favorably in the media. Company Overall Sentiment Sareum Positive Proactis Neutral Which has better valuation & earnings, SAR or PHD? Proactis has higher revenue and earnings than Sareum. Sareum is trading at a lower price-to-earnings ratio than Proactis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSareumN/AN/A-£5.28M-£2.60-5.58Proactis£48.90M0.00N/A-£20.70N/A SummaryProactis beats Sareum on 4 of the 7 factors compared between the two stocks. Get Sareum News Delivered to You Automatically Sign up to receive the latest news and ratings for SAR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAR vs. The Competition Export to ExcelMetricSareumBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£20.02M£216.56M£6.17B£2.60BDividend Yield1.10%3.81%5.72%5.37%P/E Ratio-5.583.2629.78400.34Price / SalesN/A5,412.19495.0098,387.42Price / Cash11.3213.1936.5527.90Price / Book5.5690.8512.067.30Net Income-£5.28M-£90.99M£3.32B£5.88B7 Day Performance-10.49%-0.12%1.30%0.77%1 Month Performance-46.20%3.37%5.93%1.01%1 Year Performance-39.58%568.69%61.87%117.80% Sareum Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SARSareumN/AGBX 14.50-12.1%N/A-29.5%£20.02MN/A-5.583,211News CoveragePositive NewsEarnings ReportHigh Trading VolumePHDProactisN/AN/AN/AN/A£70.69M£48.90M-3.57516FENFrenkel Topping GroupN/AGBX 48.50-1.0%N/A+8.8%£59.60M£40.46M1,564.52307NMTNeometalsN/AN/AN/AN/A£57.39MN/A-1.87N/AIGRIG Design Group1.8698 of 5 starsGBX 55-1.8%GBX 120+118.2%-54.8%£52.42M£729.27M-52.583,092GLVGlenveagh PropertiesN/AGBX 1.85+0.3%N/A+11.9%£9.80M£1.06B8.39502TSITwo Shields Investments Plc (TSI.L)N/AN/AN/AN/A£6.15MN/A-1.053CGOContangoN/AGBX 0.77+2.7%N/AN/A£5.84MN/A-114.932,219News CoverageInsider TradeGap UpMYNMayan EnergyN/AN/AN/AN/A£5.28M-£3K-0.235Gap UpIDEIDE GroupN/AN/AN/AN/A£3.60M£13.64M-18.13237EVGEvgen PharmaN/AN/AN/AN/A£3.42MN/A-80.0010 Related Companies and Tools Related Companies Proactis Competitors Frenkel Topping Group Competitors Neometals Competitors IG Design Group Competitors Glenveagh Properties Competitors Two Shields Investments Plc (TSI.L) Competitors Contango Competitors Mayan Energy Competitors IDE Group Competitors Evgen Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:SAR) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredApple's secret partnerThe Tiny Company Apple Can’t Live Without A tiny company holds the key to Apple’s biggest breakthrough sinc...The Oxford Club | SponsoredTrump cannot stop this trainGallup reports that two-thirds of Americans now view socialism favorably — a shocking shift that one analyst s...Porter & Company | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredGold surges past $4,200 … but this has beat gold by 1,000xGold has surged past $4,200 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sareum Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Sareum With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
